NEPC does not secrete prostate-specific antigen (PSA) and is a highly aggressive subtype of prostate cancer characterized by the following features: unresponsiveness to hormone therapy and expression of neuroendocrine markers such as enolase 2 (NSE) [10, 11]. This evidence concerns the gene ENO2 and prostate carcinoma.